<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00275990</url>
  </required_header>
  <id_info>
    <org_study_id>JETSTENT</org_study_id>
    <nct_id>NCT00275990</nct_id>
  </id_info>
  <brief_title>AngioJET Thrombectomy and STENTing for Treatment of Acute Myocardial Infarction</brief_title>
  <official_title>AngioJET Rheolytic Thrombectomy Before Direct Infarct Artery STENTing in Patients Undergoing Primary PCI for Acute Myocardial Infarction: [JETSTENT] Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boston Scientific Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boston Scientific Corporation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether prompt removal of thrombus (blood clot)&#xD;
      from a blocked coronary artery using the AngioJet rheolytic thrombectomy device will result&#xD;
      in improved blood flow within the heart and a smaller final infarct size (reduced injury to&#xD;
      the heart muscle).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Occlusive thrombosis triggered by a disrupted or eroded atherosclerotic plaque is the&#xD;
      anatomic substrate of most acute myocardial infarctions (AMI). Macro- and microembolization&#xD;
      of thrombus during percutaneous coronary intervention (PCI) in AMI is frequent and may result&#xD;
      in obstruction of the microvessel network, and decreased efficacy of reperfusion and&#xD;
      myocardial salvage. Direct stenting without predilation or postdilation is the most&#xD;
      simplistic approach to the problem of embolization, and may decrease embolization and the&#xD;
      incidence of the no-reflow phenomenon. Other approaches to the problem of microvessel&#xD;
      embolization include percutaneous rheolytic thrombectomy (RT) with the AngioJet catheter&#xD;
      before stent implantation. The objectives of the study are: to assess whether RT before&#xD;
      direct infarct artery stenting results in improved reperfusion success in patients with acute&#xD;
      ST-segment elevation myocardial infarction (STEMI) and angiographically evident thrombus; and&#xD;
      to validate a technique for use of the AngioJet RT catheter in the treatment of STEMI.&#xD;
&#xD;
      Comparisons: Treatment with AngioJet RT immediately before direct infarct artery stenting&#xD;
      versus direct stenting alone, in patients with STEMI and angiographically visible thrombus&#xD;
      presenting within 6 hours of symptom onset for primary PCI.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2005</start_date>
  <completion_date type="Actual">August 2010</completion_date>
  <primary_completion_date type="Actual">October 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ST-segment resolution at 30 minutes post-PCI, assessed by 12-lead ECG</measure>
    <time_frame>30 minutes post procedure</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Infarction size measured by technetium Tc 99m sestamibi imaging at 30 days</measure>
    <time_frame>30 days post-procedure</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Post-procedure- TIMI flow, TIMI myocardial blush, and corrected TIMI frame count</measure>
    <time_frame>post-procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>30 days- Technetium Tc 99m sestamibi infarct size, MACE</measure>
    <time_frame>30 days post-procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>6 months- MACE</measure>
    <time_frame>6 months post-procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>12 months- MACE</measure>
    <time_frame>12 months post-procedure</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">501</enrollment>
  <condition>Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>thrombectomy before stenting</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>thrombectomy before stenting</description>
  </arm_group>
  <arm_group>
    <arm_group_label>directing stenting alone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>directing stenting alone</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>rheolytic thrombectomy with direct stenting</intervention_name>
    <arm_group_label>thrombectomy before stenting</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>direct stenting</intervention_name>
    <arm_group_label>directing stenting alone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient age &gt; 18 years&#xD;
&#xD;
          -  ST-segment elevation myocardial infarction&#xD;
&#xD;
          -  Angiographically visible thrombus&#xD;
&#xD;
          -  Presentation within 6 hours of symptom onset for primary percutaneous coronary&#xD;
             intervention&#xD;
&#xD;
          -  Patient, or relative or legal guardian,provides written informed consent&#xD;
&#xD;
          -  Patient has no childbearing potential or is not pregnant&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior administration of thrombolysis for current MI&#xD;
&#xD;
          -  Participation in another Study&#xD;
&#xD;
          -  Major surgery within past 6 weeks&#xD;
&#xD;
          -  History of stroke within 30 days, or any history of hemorrhagic stroke&#xD;
&#xD;
          -  Severe hypertension (systolic BP &gt; 200 mm Hg or diastolic BP &gt; 110 mm Hg) not&#xD;
             controlled on antihypertensive therapy&#xD;
&#xD;
          -  Known neutropenia ( &lt;1000 neutrophils per mm3) or known severe thrombocytopenia (&lt;&#xD;
             50,000 platelets per mm3)&#xD;
&#xD;
          -  Known prior history of renal insufficiency&#xD;
&#xD;
          -  Co-morbidities with expected survival &lt; 1 year&#xD;
&#xD;
          -  Patient unwilling to receive blood products&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Antoniucci, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Azienda Ospedaliero-Universitaria Careggi, Florence, ITALY</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Antonio Colombo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>San Raffaelle Hospital, Milan ITALY</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Careggi Hospital, Division of Cardiology</name>
      <address>
        <city>Florence</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Antoniucci D, Valenti R, Migliorini A, Parodi G, Memisha G, Santoro GM, Sciagr√† R. Comparison of rheolytic thrombectomy before direct infarct artery stenting versus direct stenting alone in patients undergoing percutaneous coronary intervention for acute myocardial infarction. Am J Cardiol. 2004 Apr 15;93(8):1033-5.</citation>
    <PMID>15081450</PMID>
  </reference>
  <results_reference>
    <citation>Migliorini A, Stabile A, Rodriguez AE, Gandolfo C, Rodriguez Granillo AM, Valenti R, Parodi G, Neumann FJ, Colombo A, Antoniucci D; JETSTENT Trial Investigators. Comparison of AngioJet rheolytic thrombectomy before direct infarct artery stenting with direct stenting alone in patients with acute myocardial infarction. The JETSTENT trial. J Am Coll Cardiol. 2010 Oct 12;56(16):1298-306. doi: 10.1016/j.jacc.2010.06.011. Epub 2010 Aug 5.</citation>
    <PMID>20691553</PMID>
  </results_reference>
  <verification_date>October 2014</verification_date>
  <study_first_submitted>January 10, 2006</study_first_submitted>
  <study_first_submitted_qc>January 11, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 12, 2006</study_first_posted>
  <last_update_submitted>October 8, 2014</last_update_submitted>
  <last_update_submitted_qc>October 8, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 9, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>coronary thrombectomy</keyword>
  <keyword>thrombectomy for acute myocardial infarction</keyword>
  <keyword>C14.280.647.500</keyword>
  <keyword>C14.907.553.355.500</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

